Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Protecting patient privacy the new fashioned way

Protecting patient privacy has been recognized as the duty of health-care providers for aHealth Insurance Portability and Accountability Actbout as long as doctors have seen patients. Since 1996, that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act.

25 Sep 2008

Discovery provides model for Alzheimer's breakthrough

Sydney researchers have made a major breakthrough that will lead to a greater understanding of the causes of and treatments for neurodegenerative diseases.

24 Sep 2008

British scientists to develop blood test for Alzheimer's

Researchers from Nottingham's two universities are joining forces to develop a simple blood test to diagnose Alzheimer's disease.

17 Sep 2008

A blood marker may indicate Alzheimer's risk

A simple blood test capable of predicting if a person might develop Alzheimer's disease is within sight, and could eventually be used to help scientists reverse onset of the disease in those most at risk.

17 Sep 2008

Vicor Technologies announces publication of positive results in study conducted in collaboration with U.S. Army

Vicor Technologies, Inc. today announced publication of the results of its first clinical study conducted in collaboration with the U.S. Army Institute of Surgical Research (USAISR).

15 Sep 2008

Grand Rapids Press examines Alzheimer's disease care among Hispanics

The Grand Rapids Press on Tuesday examined the "cultural tightrope" faced by some Hispanics who seek long-term care for a family member with Alzheimer's disease.

11 Sep 2008

Receptor activation protects retina from diabetes destruction

A drug known for it pain-relieving power and believed to stimulate memory appears to prevent this retinal damage that leads to vision loss, researchers say.

9 Sep 2008

Older people can improve their memory and postpone dementia with exercise

A study by Australian researchers has found that regular, moderate exercise may help improve memory in older people and delay the onset of dementia.Older people can improve their memory and postpone dementia with exercise

3 Sep 2008

Oxidative stress: mechanism of cell death clarified

Dr. Marcus Conrad of the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Zentrum Munchen has decrypted the molecular mechanism through which the death of cells is caused by oxidative stress.

3 Sep 2008

Just a little exercise each day helps prevent memory deterioration

West Australian health experts are urging older people to get active after proving for the first time that just 20 minutes of activity each day can prevent memory deterioration.

2 Sep 2008

Vitamin B deficiency may cause vascular cognitive impairment

A deficiency of B-vitamins may cause vascular cognitive impairment, according to a new study. Researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA) at Tufts University used an experimental model to examine the metabolic, cognitive, and microvascular effects of dietary B-vitamin deficiency.

2 Sep 2008

New stem cell tools to aid drug development

Scientists have designed, developed and tested new molecular tools for stem cell research to direct the formation of certain tissue types for use in drug development programmes.

2 Sep 2008

Bryostatin extends stroke treatment time to 24 hours, repairs brain tissue

Scientists at the Blanchette Rockefeller Neurosciences Institute (BRNI) have discovered that Bryostatin -- and a related class of drugs discovered at BRNI -- administered 24 hours after stroke can rescue and repair brain tissue. These findings are markedly advanced compared to current stroke treatments that must be administered within three hours and are unable to repair damaged brain tissue.

1 Sep 2008

Mylan's Alphapharm victorious in Razadyne patent challenge

Mylan Inc. has announced that its subsidiary Alphapharm Pty Limited won a favorable decision in patent litigation against it and Barr Laboratories Inc. relating to Galantamine Tablets, USP, the generic version of Ortho-McNeil's Razadyne Tablets, 4 mg, 8 mg and 12 mg.

31 Aug 2008

Ortho-McNeil to appeal patent ruling on Razadyne

Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced that it will appeal yesterday's decision by the U.S. District Court of Delaware, which ruled the patent for Razadyne (galantamine hydrobromide) is invalid.

28 Aug 2008

New sleep lab to benefit shift-workers

Two specialist laboratories opening night at the University of Sydney will shed light on the impact of sleep and circadian disruption in medical disorders and shift-workers, and the neurobiological mechanisms underlying substance abuse and depression.

21 Aug 2008

New therapeutic approaches to protect neurons from inflammation and toxicity-induced neurodegeneration

New research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, provides evidence that one of the only naturally occurring fatty acids in the brain that has the ability to interact with the receptors originally identified as the targets of THC (the psychoactive component of marijuana) can help to protect brain cells from neurodegenerative diseases like Alzheimer's and Parkinson's.

20 Aug 2008

Addiction drug Vigabatrin proves successful in animal weight loss study

Vigabatrin, a medication proposed as a potential treatment for drug addiction by scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, also leads to rapid weight loss and reduced food intake according to a new animal study from the same research group.

20 Aug 2008

When the patient can't make the decision

Family members are often called upon to make medical choices for patients who are unable to do so themselves. Researchers led by Alexia Torke, M.D., of the Indiana University School of Medicine and the Regenstrief Institute, Inc., studied how physicians treating these patients interacted with surrogate decision-makers.

18 Aug 2008

First drug for Huntington's disease approved for use in the U.S.

Huntington's disease is a fatal, inherited neurodegenerative disorder for which there is no cure and usually affects people in their 30s and 40s, but some patients are affected as early as childhood, while others aren't affected until they are older.

18 Aug 2008